NeuroSigma
PrivateLast Round
Corporate Funding
Dec 15, 2025
Total Funding Raised
$9.6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NeuroSigma operates in Healthcare & Life Sciences and is based in Los Angeles, California. Its latest recorded funding round was a Corporate Funding round in December 2025.
NeuroSigma is a bioelectronic medical device company that develops and commercializes non-invasive trigeminal nerve stimulation (TNS) technologies for treating disorders such as pediatric ADHD, epilepsy, and depression.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Mental Health, Biotechnology
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroSigma Comparables
Compare NeuroSigma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurolief | 77% | |
| electroCore | 73% | |
| Sooma | 72% |
For institutional investors. Book with your work email.
NeuroSigma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 15, 2025 | ||||
| Debt Conversion | Dec 8, 2021 | ||||
| Corporate Funding | Dec 8, 2021 | ||||
| Corporate Funding | Sep 21, 2020 | ||||
| Grant | Feb 4, 2013 |
For institutional investors. Book with your work email.
NeuroSigma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| Checkmate Capital | Corporate Funding |
| National Institute of Neurological Disorders and Stroke | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 25, 2026
Grew 43% QoQ, from 7 to 10 employees.
- Apr 22, 2026
Monthly visitors grew 115% MoM, reaching 4K.
For institutional investors. Book with your work email.
NeuroSigma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroSigma's valuation, stock price, and market status.
Is NeuroSigma a public or private company?
NeuroSigma is a private company.
What is the current stock price of NeuroSigma?
NeuroSigma is a private company, so its shares have no public market price. Caplight tracks NeuroSigma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroSigma worth (valuation)?
Valuation information for NeuroSigma is not publicly available.
Can I buy NeuroSigma stock?
NeuroSigma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroSigma's last funding round?
NeuroSigma's most recent funding round was Corporate Funding on December 15, 2025.
Who are the main investors in NeuroSigma?
Key investors in NeuroSigma include Checkmate Capital, National Institute of Neurological Disorders and Stroke.
Will NeuroSigma IPO soon?
No public IPO plans have been announced for NeuroSigma.
How can I track NeuroSigma secondary market activity?
Caplight tracks bids, offers, and trades in NeuroSigma's shares on secondary markets.